Nouveau Life Pharmaceuticals (NOUV) to Launch Affiliate Sales Program

FORT LAUDERDALE, Fla., June 22, 2012 /PRNewswire/ -- Nouveau Life Pharmaceuticals, Inc. (Pink Sheets: NOUV), a provider of quality all-natural dietary supplements, announced today that the Company is developing a formal Affiliate Sales Program.

Nouveau Life is currently developing an Affiliate Sales Program as part of its larger strategic marketing plan. The Nouveau Life Affiliate Sales Program will be based on the pay-for-performance model; affiliate partners will be paid a commission on each product sale they generate.  

"An affiliate program is an extremely effective marketing tool to quickly increase brand awareness and product exposure and, in turn, generate more revenue," explained Nouveau Life CEO Melissa Walker. "When implemented properly, an affiliate sales program can grow sales exponentially while requiring little operating capital."

Affiliate partners will be allowed to market and sell all of Nouveau Life's current products, which include Azul: Male Enhancer™, Azul Instant™, New Life Naturals: For Her Senses™, and New Life Naturals: For Your Weight Loss™. As Nouveau Life releases new products to the public, those products will also be added to the Affiliate Sales Program. Affiliate partners will be provided with exclusive sales and marketing tools such as banner ads, coupon codes, promotional email text, and product images.

The Nouveau Life Affiliate Sales Program is slated to be launched within the next two weeks. Watch for additional information on the Nouveau Life website at www.nlpnaturals.com.

About Nouveau Life Pharmaceuticals

The Company, formerly known as Hybrid Fuels, Inc., was incorporated in the state of Nevada in 1998 as Polo Equities. It has primarily been a development stage company with management focused on developing innovative business opportunities and further advancing technologies.

Forward-Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future results to differ materially from the forward-looking statements. You should consider these factors in evaluating the statements herein, and not rely on such statements. The forward-looking statements in this release are made as of the date hereof and Nouveau Life Pharmaceuticals, Inc. undertakes no obligation to update such statements.

CONTACT:

Nouveau Life Pharmaceuticals, Inc. - 954-903-2993

SOURCE Nouveau Life Pharmaceuticals, Inc.